Niagen Bioscience, Inc. is a bioscience company focused on healthy aging and NAD+ science. The company develops and commercializes proprietary ingredient technologies, including food-grade and pharmaceutical-grade Niagen, a form of nicotinamide riboside. It operates through a consumer products segment selling Tru Niagen dietary supplements via direct-to-consumer channels and international distributors, and an ingredients segment supplying raw materials to consumer product manufacturers and FDA-registered outsourcing facilities for injectable formulations. The company also maintains an analytical reference standards and services segment, providing quality-control products and research services to the dietary supplement, food, cosmetic, and pharmaceutical industries, though it has entered into an agreement to sell this segment. Additionally, Niagen Bioscience pursues pharmaceutical development of NAD+ precursors for therapeutic applications in rare diseases. The company conducts research through its ChromaDex External Research Program, collaborating with universities and institutions to advance NAD+ biology. Formerly known as ChromaDex Corporation, the company changed its name in March 2025.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage niagenbioscience.com
Sector Healthcare IR page investors.niagenbioscience.com/overview/default.aspx
Tags
nad+ precursors, nicotinamide riboside, dietary supplements, healthy aging, cellular metabolism, pharmaceutical ingredients, analytical reference standards, clinical research, rare diseases, food ingredients, Niagen, Tru Niagen, Niagen Plus, ChromaDex External Research Program, CERP, ChromaDex Inc., Healthspan Research LLC
Press page niagenbioscience.com/pages/news

Metrics

Valuation  
Market cap $ 230.768M
Market cap (USD) $ 230.768M
P/E 24.33
PEG —
P/BV 2.78
P/S 1.89
P/OCF 47.27
P/FCF 17.47
Dividend yield —
Turnover / mcap —
Returns  
ROE 28.3%
ROI 128.2%
ROIC 114.7%
Profit margin 13.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 69
Quality score 47.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007
Revenue 129.423M 99.597M 83.57M 72.05M 67.449M 59.257M 46.291M 31.557M 21.201M 26.811M 22.014M 15.313M 10.161M 11.61M 8.113M 7.566M 7.566M 5.778M 4.506M
Net profit 17.382M 8.55M -4.938M -16.54M -27.128M -19.925M -32.147M -33.316M -11.378M -2.928M -2.771M -5.388M -4.42M -11.662M -7.895M -2.052M -2.052M -907.568K -2.104M
Free cash flow 13.212M 11.946M 6.969M -15.432M -24.572M — -21.182M -22.229M -10.972M -4.442M -2.636M -2.704M -4.043M -10.144M -4.249M -2.831M -2.831M -580.659K -2.339M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007
Share price 6.36 5.31 1.43 1.68 3.74 4.8 4.31 3.43 5.88 3.31 — — — — — — — — —
Price performance 12m 0.2 2.71 -0.15 -0.55 -0.22 0.11 0.26 -0.42 0.78 — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 5.85M 5.34M 4.36M 2.18M 2.69M 5.23M 8.48M 5.23M 7.77M 9.74M
↳ YoY growth +138.8% -8.8% -18.3% -50.1% +23.9% +94.0% +62.3% -38.3% +48.4% +25.4%
↳ 5y CAGR +51.9% +22.4% +39.0% +2.7% +1.9% -2.2% +9.7% +3.7% +29.0% +29.3%
Borrowings, current (USD) 0.00 310,000 137,000 — — — — — — —
Borrowings, non-current (USD) 0.00 — — — — — — — — —
Lease liabilities (USD) — — 310,000 1.72M 1.64M 4.7M 4.26M 3.28M 2.65M 2.82M
Cash and deposits (USD) — — 22.6M 18.8M 16.7M 28.2M 20.3M 27.2M 44.5M 64.8M
Intangible assets (USD) 486,226 1.65M 1.55M 1.31M 1.08M 857,000 671,000 510,000 359,000 5.66M
Right-of-use assets (USD) — — 0.00 891,000 1.23M 4.35M 3.52M 2.4M 1.73M 2.19M
Cash flow detail
Operating cash flow (USD) -2.94M -9.8M -20.9M -20.4M -10.6M -24.2M -15.1M 7.12M 12.1M 13.5M
Purchases of property, plant and equipment (USD) -1.5M -1.17M -1.32M -743,000 — — — — — —
Purchases of intangible assets (USD) -220,000 -183,958 -131,000 -10,000 -18,000 0.00 — — — —
Change in receivables (cash effect) (USD) -4.11M -937,093 -1.11M 44,000 — — — — — —
Change in inventories (cash effect) (USD) 240,851 -2.18M 2.45M 3.29M 148,000 -1.92M -1.08M 152,000 5.33M -11.6M
Change in payables (cash effect) (USD) -245,670 -2.36M 5.83M 78,000 -181,000 978,000 -744,000 553,000 -1.07M 2.27M
Share buybacks (cash effect) (USD) — 0.00 -404,000 — — — — — 0.00 -251,000
Interest paid (cash effect) (USD) -261,738 -57,024 -41,000 -33,000 -13,000 -1,000 -1,000 -2,000 -1,000 -1,000
Share-based compensation (USD) 1.19M 4.6M 6.37M 7.17M 6.94M 6.2M 5.74M 4.75M 3.66M 6.07M
Operating cash flow before change in receivables (USD) 1.18M -8.87M -19.8M -20.5M — — — — — —
Free cash flow (OCF - PPE - intangibles) (USD) -4.66M -11.2M -22.4M -21.2M — — — — — —
Income detail
Research and development expense (USD) 2.52M 4.01M 5.48M 4.42M 3.73M 3.83M 4.83M 4.96M 6.02M 6.33M
↳ 5y CAGR +92.0% +95.2% +110.0% +53.8% +33.2% +8.7% +3.8% -2.0% +6.4% +11.1%
Provision for credit losses (USD) 713,122 -411,475 -132,000 2.23M 2.58M 46,000 63,000 964,000 -1.26M -1.22M
Credit cost ratio (credit losses / average receivables) (%) 17.2% 7.4% 2.7% 68.2% 105.8% 1.2% 0.9% 14.1% 19.3% 13.9%
Reported Mar 15, 2018 Mar 7, 2019 Aug 6, 2020 Aug 6, 2020 Mar 14, 2022 Mar 14, 2022 Mar 8, 2023 May 8, 2024 Mar 4, 2026 Mar 4, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 4, 2026

Launched Niagen™ Plus Niagen™ Liquid At-Home Injections

Launched Niagen NanoCloud™, the first dermatologist-tested topical product

Launched “Don’t Get Old. Age Better.®,” a new brand campaign

Net sales of $27.2 million, including $23.3 million from Tru Niagen

Generated $2.6 million of operating cash flow

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced its operational updates and financial results for the third quarter of 2026.

Third Quarter 2026 Financial and Business Highlights

  • Total net sales of $27.2 million, including $23.3 million from Tru Niagen®. Direct to consumer sales on the Company’s website grew by 13% year-over-year.
  • Gross margin of 62.9%, which the Company believes reflects the strength of its operational foundation.
  • Net loss of $1.2 million, with basic and diluted loss per share of $(0.01).
  • Adjusted EBITDA, a non-GAAP measure, was positive at $0.5 million.
  • Total cash provided by operations of $4.2 million during the nine months ended September 30, 2026, and $2.6 million in the three-month period.
  • The Company ended the quarter with $69.5 million in cash and cash equivalents, as compared to $66.7 million in cash and cash equivalents for the period ended June 30, 2026.
  • Launched the liquid, ready-to-inject Niagen™ At-Home Injection Kit, formulated with pharmaceutical grade Niagen nicotinamide riboside (NR) through the Niagen™ Plus telehealth platform.
  • Launched Tru Niagen® Skincare, a permanent new category in the core Tru Niagen line. The inaugural product in this new category is Niagen NanoCloud™, the first dermatologist-tested topical product powered by Niagen NR.
  • Launched “Don't Get Old. Age Better®,” a new brand campaign for the Niagen® brand and sub-brands Tru Niagen® and Niagen Plus™, featuring 11-time world champion surfer Kelly Slater and more than 20 partners, across sports, entertainment, and medicine.
  • Announced a Start-Up Agreement with Mass General Brigham (MGB) to begin detailed planning for what is envisioned to be the largest and most comprehensive clinical trial of Niagen to date.
  • NAD Pharmaceuticals engaged Red Sky Partners, a life sciences strategic advisory firm, to support the advancement of NB4168, the Company’s small molecule investigational drug candidate, targeting rare genetic diseases and aging-related disorders.
  • Expanded access to Tru Niagen by launching on Walmart.com and diversified the e-commerce marketplace presence and expanded retail footprint by launching at nearly 300 GNC and Sam’s Club locations across 44 states combined.
  • Announced the publication of a new peer-reviewed analysis of past clinical studies in Aging Cell examining the effects of Niagen® supplementation was associated with reduced muscle epigenetic age acceleration measured by the Muscle Epigenetic Age Test (MEAT) clock.

“During the third quarter, we navigated near-term commercial headwinds while continuing to generate positive adjusted EBITDA and $2.6 million in operating cash flow and make tangible progress across the Niagen platform,” said Rob Fried, Chief Executive Officer. “We advanced NB4168, expanded Tru Niagen distribution, established skincare as a permanent category, launched a more convenient ready-to-inject Niagen Plus product, and invested in brand awareness and long-term clinical research. As stated before, we view 2026 as an investment year, and believe the progress we are making across consumer health, ingredients, injectables, skincare, and pharmaceuticals provides a strong springboard for meaningful growth in 2027 and beyond.”

2026 Outlook and Strategic Priorities:

For the full year 2026, the Company expects direct website revenues to grow by 15% to 20% year-over-year and overall e-commerce to grow by approximately 5% year-over-year. The Company expects the performance of the remainder of its consumer business to offset the growth of the e-commerce business. The ingredient business is expected to be lower than the prior year, primarily due to decreased volume from key ingredient partners due to competitive market dynamics, although additional ingredient partners were added in Q3 2026 and more are expected to be added in the near term. The Company is planning to introduce a lower-cost NR salt form, patented by Niagen Bioscience, which is expected to reduce cost of goods sold and strengthen the ingredient business. The Company expects Niagen Plus growth and new skincare partnerships to become meaningful contributors beginning in 2027.

The Company believes 2026 is an important year of strategic investment and continues to expect operating expenses to increase as it invests across commercial, research and administrative functions to support these strategic priorities, while continuing to focus on disciplined capital allocation and positive cash flow from operations.

Investor Conference Call

A live webcast will be held Wednesday, November 4, 2026 at 4:30 p.m. Eastern Standard Time (1:30 p.m. Pacific Standard Time) to discuss Niagen Bioscience’s third-quarter financial results and provide a general business update.

To listen to the webcast, or to view the earnings press release and its accompanying financial exhibits, please visit the Investor Relations section of Niagen Bioscience’s website at https://investors.niagenbioscience.com . The toll-free dial-in information for this call is 1-833-461-5787 with Conference ID: 198389474. The webcast will be recorded, and will be available for replay via the website from 7:30 p.m. Eastern Standard Time on November 4, 2026.

Important Note on Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects,” “anticipates,” “intends,” “estimates,” “plans,” “potential,” “possible,” “probable,” “believes,” “seeks,” “may,” “will,” “should,” “could,” “predicts,” “projects,” “continues,” “would” or the negative of such terms or other similar expressions. Forward-looking statements include without limitation, statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the quotation from Niagen Bioscience’s Chief Executive Officer, statements related to the Company’s 2026 financial outlook including but not limited to net sales, gross margin, expenses, investment priorities, and commercialization efforts and statements regarding Niagen® and Niagen Plus clinical initiatives and statements attributable to management.

Risks that contribute to the uncertain nature of the forward-looking statements include: our relationships with major customers; a decline in general economic conditions nationally and internationally; the market and size of the vitamin, mineral and dietary supplement market and the intravenous market; decreased demand for our products and services; market acceptance of our products; the success of our brand campaign and other marketing investments; interruptions in our ability to sell products through third-party online marketplaces; the ability to protect our intellectual property rights; impact of any litigation or infringement actions brought against us; regulation of our advertising, marketing and sales practices by the FTC and state authorities; competition from other providers and products, including other supplements such as NMN; risks in product development; our ability to develop pharmaceutical business; the Company's therapeutic pipeline, including NB4168, preclinical and IND-enabling studies, and regulatory designations and development plans; inability to raise capital to fund continuing operations or new product development; changes in government regulation or regulatory priorities of government officials; the ability to complete customer transactions and capital raising transactions; inflationary conditions and adverse economic conditions; our history of operating losses; the growth and profitability of our product sales; our ability to maintain and grow sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; risks of conducting business in China; unanticipated developments in and risks related to the Company’s ability to secure adequate quantities of pharmaceutical-grade Niagen in a timely manner; the Company’s ability to obtain appropriate contracts and arrangements with U.S. FDA-registered 503B outsourcing facilities required to compound and distribute pharmaceutical-grade Niagen to clinics; the Company’s ability to remain on the U.S. FDA Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Category 1 list; the Company’s ability to maintain and enforce the Company’s existing intellectual property and obtain new patents; whether the potential benefits of NRC can be further supported; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities, including with respect to products seeking to compete in our market; mislabeling or other misleading marketing practices by competitors; economic and market instability, including as a result of tariffs or trade conflicts; and the risks and uncertainties associated with our business and financial condition in general, described in our filings with the Securities and Exchange Commission (SEC), including, without limitation, our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q as filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Niagen Bioscience undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

About Niagen Bioscience, Inc.:

Niagen Bioscience is a global bioscience company focused on healthy aging. The Company is a leader in research on NAD+ (nicotinamide adenine dinucleotide), an essential coenzyme that supports cellular metabolism and declines with age. Niagen Bioscience is the innovator of nicotinamide riboside (commonly referred to as “NR”), a patented NAD+ precursor commercialized as Niagen®, available in both food-grade and pharmaceutical-grade forms. Nicotinamide riboside and other NAD+ precursors are protected by Niagen Bioscience’s patent portfolio.

The Company markets its consumer supplement Tru Niagen® and develops and supplies Niagen® as a proprietary ingredient to partners across the health and wellness and pharmaceutical sectors. Niagen Bioscience is also advancing research and development of NAD+ precursor-based technologies for potential therapeutic applications. Follow us on X (formerly Twitter) @NiagenBio and Instagram @TruNiagen and @NiagenPlus and subscribe to our latest news via our website accessible at www.NiagenBioscience.com to which Niagen Bioscience regularly posts copies of its press releases as well as additional updates and financial information about the Company.

Niagen Bioscience, Inc. and Subsidiaries
Unaudited Condensed Consolidated Statements of Operations
Three Months Ended September 30, Nine Months Ended September 30,
2026 2025 2026 2025
(In thousands, except per share data)
Sales, net $ 27,192 $ 33,986 $ 88,451 $ 95,584
Cost of sales 10,087 12,058 32,056 34,099
Gross profit 17,105 21,928 56,395 61,485
Operating expenses:
Sales and marketing 8,713 8,768 28,518 25,092
Research and development 1,796 1,795 4,790 4,620
General and administrative 8,183 7,129 22,398 19,580
Total operating expenses 18,692 17,692 55,706 49,292
Operating income (loss) (1,587 ) 4,236 689 12,193
Nonoperating income:
Interest income, net 414 564 1,161 1,575
Gain on sale of operating segment — — 4,781 —
Income (loss) before provision for income taxes (1,173 ) 4,800 6,631 13,768
Provision for income taxes — 222 523 518
Net income (loss) $ (1,173 ) $ 4,578 $ 6,108 $ 13,250
Net income (loss) per share attributable to common stockholders:
Basic $ (0.01 ) $ 0.06 $ 0.08 $ 0.17
Diluted $ (0.01 ) $ 0.05 $ 0.07 $ 0.15
Weighted average common shares outstanding:
Basic 79,149 79,779 79,460 78,953
Diluted 79,149 86,619 82,822 85,487
Niagen Bioscience, Inc. and Subsidiaries
Unaudited Condensed Consolidated Balance Sheets
(In thousands) September 30, 2026 December 31, 2025
Assets
Current assets:
Cash and cash equivalents, including restricted cash of $152 for both periods presented $ 69,509 $ 64,788
Trade receivables, net of allowances of $103 and $147, respectively 6,840 9,741
Inventories 20,524 20,424
Assets held for sale — 541
Prepaid expenses and other assets 3,342 1,312
Total current assets 100,215 96,806
Leasehold improvements and equipment, net 1,216 1,323
Intangible assets, net 5,136 5,660
Right-of-use assets, net 1,657 2,192
Other long-term assets 470 425
Total assets $ 108,694 $ 106,406
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable $ 11,503 $ 10,796
Accrued expenses 3,933 7,722
Current maturities of operating lease obligations 799 1,002
Current deferred consideration liability 535 —
Customer deposits 137 399
Total current liabilities 16,907 19,919
Deferred revenue 2,162 2,674
Operating lease obligations, less current maturities 1,278 1,815
Deferred consideration liability, less current portion 5,273 5,465
Total stockholders’ equity 83,074 76,533
Total liabilities and stockholders’ equity $ 108,694 $ 106,406
Niagen Bioscience, Inc. and Subsidiaries
Unaudited Condensed Consolidated Statements of Cash Flows
Nine Months Ended September 30,
(In thousands) 2026 2025
Net cash provided by / (used in):
Operating activities $ 4,203 $ 12,825
Investing activities 5,101 (191 )
Financing activities (4,583 ) 6,996
Net increase in cash and cash equivalents 4,721 19,630
Cash and cash equivalents beginning of period 64,788 44,660
Cash and cash equivalents at end of period $ 69,509 $ 64,290
Niagen Bioscience, Inc. and Subsidiaries
Unaudited Reconciliation of Non-GAAP Financial Measures
Reconciliation of Net Income to Adjusted EBITDA
(In thousands) Q3 2026 Q2 2026 Q1 2026 Q4 2025 Q3 2025
Net income, as reported $ (1,173 ) $ 963 $ 6,318 $ 4,132 $ 4,578
Adjustments:
Interest income, net (414 ) (372 ) (375 ) (552 ) (564 )
Provision for income taxes — 106 417 292 222
Depreciation 115 117 116 139 157
Amortization of intangibles 175 174 175 60 38
Noncash lease expense 183 179 173 169 164
Share-based compensation 1,522 1,723 1,716 1,748 1,756
Severance and restructuring 47 144 79 53 10
Gain on settlement of royalty obligation (1) — — — (1,983 ) —
Gain on sale of operating segment (2) — 3 (4,784 ) — —
Adjusted EBITDA $ 455 $ 3,037 $ 3,835 $ 4,058 $ 6,361
(1) Represents a gain related to the settlement of royalty obligations from a settlement agreement with Queen's University Belfast.
(2) Represents a gain related to the sale of the Company’s Analytical Reference Standards and Services operating segment.

Non-GAAP Financial Information:

To supplement Niagen Bioscience’s unaudited financial data presented in accordance with generally accepted accounting principles (GAAP), the Company has presented Adjusted EBITDA, a non-GAAP financial measure. Niagen Bioscience believes the presentation of this non-GAAP financial measure provides important supplemental information to management and investors and enhances the overall understanding of the Company’s historical and current financial operating performance. The Company believes disclosure of the non-GAAP financial measure has substance because the excluded expenses are infrequent in nature, are variable in nature or do not represent current cash expenditures. Further, such non-GAAP financial measure is among the indicators the Company uses as a basis for evaluating the Company’s financial performance as well as for planning and forecasting purposes. Accordingly, disclosure of this non-GAAP financial measure provides investors with the same information that management uses to understand the Company’s economic performance year-over-year.

Adjusted EBITDA is defined as net income before (a) interest, (b) provision for income taxes, (c) depreciation, (d) amortization, (e) non-cash share-based compensation costs, (f) severance and restructuring expense and (g) other infrequent items, including gains recognized related to the sale of an operating segment and a royalty settlement. While Niagen Bioscience believes that this non-GAAP financial measure provides useful supplemental information to investors, there are limitations associated with the use of such measure. This measure is not prepared in accordance with GAAP and may not be directly comparable to similarly titled measures of other companies due to potential differences in the method of calculation. Management compensates for these limitations by relying primarily on the Company’s GAAP results and by using Adjusted EBITDA only supplementally and by reviewing the reconciliation of the non-GAAP financial measure to its most comparable GAAP financial measure.

Non-GAAP financial measures are not prepared in accordance with, or an alternative for, generally accepted accounting principles in the United States. The Company’s non-GAAP financial measure is not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP.

Investor Relations
KCSA Strategic Communications
Valter Pinto, Managing Director
1 (212) 896-1254
[email protected]

Media Relations
Kendall Knysch
Senior Director of Media Relations & Partnerships
+1 (310) 405-5227
[email protected]

Source: Niagen Bioscience, Inc

View All News

October 22, 2026

Liquid formulation of Niagen™ Plus simplifies at-home administration and is the only at-home injection with clinical outcomes associated with reduced fatigue and improved sleep and skin

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of the clinician-directed, prescription-only pharmaceutical-grade Niagen ™ At-Home Injection Kit , featuring the Company’s first ready-to-inject liquid formulation with Niagen™ (patented nicotinamide riboside, or NR), the most studied, high-quality NAD+ precursor brand available, now available through its Niagen™ Plus telehealth platform.

Liquid formulation of Niagen Plus simplifies at-home administration and is the only at-home injection with clinical outcomes associated with reduced fatigue and improved sleep and skin

Liquid formulation of Niagen Plus simplifies at-home administration and is the only at-home injection with clinical outcomes associated with reduced fatigue and improved sleep and skin

NAD+ injections are increasingly available, yet no published clinical studies have evaluated subcutaneous (sub-q) or intramuscular (IM) NAD+ injections. In contrast, Niagen Bioscience published two pilot clinical studies of sub-q and IM Niagen injections on medRxiv. In these open-label pilot studies, injectable Niagen was well tolerated, including over 90 days of at-home use. Exploratory, self-reported outcomes were associated with reduced fatigue and improved sleep and skin. These findings require confirmation in larger, placebo-controlled studies (Nkrumah-Elie et al., 2026 ; Russ et al., 2026 ).

“The liquid Niagen At-Home Injection Kit is a meaningful step in building Niagen Plus into a scalable telehealth platform,” said Rob Fried, Chief Executive Officer of Niagen Bioscience. “Additionally, telehealth partners are central to how we intend to scale Niagen Plus. We believe a ready-to-inject format with fewer steps, backed by new pilot clinical data, provides a superior product for telehealth partners, extending reach beyond our own direct-to-patient channel.”

Each kit includes a sterile, multi-dose 5 mL vial with 500 mg of Niagen, syringes, and alcohol prep pads. Patients simply draw the clinician-prescribed dose and inject subcutaneously: fewer components, fewer steps. The program remains clinician-directed and prescription-only. Patients complete an online intake form, a licensed provider decides whether to prescribe, and if prescribed, the medication is dispensed from state-licensed 503A compounding pharmacies and shipped to their door. NiagenPlus.com is LegitScript Certified, an independent third-party certification for healthcare merchants and telehealth platforms.

Study Highlights

Two open-label pilot studies evaluated the safety and tolerability of injectable Niagen in 39 generally healthy adults with elevated fatigue (Nkrumah-Elie et al., 2026 ; Russ et al., 2026 ). Participants were randomized to 50 mg or 100 mg of Niagen by IM or sub-q injection for three days under clinical supervision, then self-administered subcutaneous Niagen at home three times weekly for an additional 90 days. Building on the safety data, these pilot studies also feature the first exploratory findings on IM and sub-q Niagen injections.

Findings:

  • Three days of supervised injections followed by 90 days of self-injection were well tolerated with no unexpected adverse events reported.
  • At-home sub-q self-administered Niagen injections were achievable under protocol-defined conditions, supporting the feasibility of at-home administration.
  • Blood NAD+ levels remained stable over the 90 days.
  • Repeated Niagen injections were associated with improvements in fatigue, sleep impairment (e.g., daytime sleepiness), and quality of life, as assessed using validated participant-reported outcome questionnaires, as well as self-reported improvements in skin health.
  • The study observed changes in markers of mitochondrial bioenergetics (efficient cellular energy production) and reductions in several oxidative stress markers (less cellular wear and tear). Because the study was open-label and not placebo-controlled, these findings are exploratory and require confirmation.

More on these findings can be found on www.aboutnad.com in the following blog posts: Nicotinamide Riboside Injections: What Two New Pilot Studies Reveal About Safety and Nicotinamide Riboside Injections: Exploratory Findings from a Two-Part Pilot Study .

For additional information on liquid Niagen At-Home Injection Kit, visit www.niagenplus.com .

About Niagen Bioscience

Niagen Bioscience, Inc. (NASDAQ: NAGE) is the global authority in healthy aging and NAD+ (nicotinamide adenine dinucleotide) science. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.

The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.

Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There’s a better way to age.

At the heart of its clinically tested product portfolio is Niagen® (patented nicotinamide riboside, or NR), the most efficient, well-researched, and high-quality NAD+ booster available. Niagen powers the Company’s consumer supplement, Tru Niagen®, the number one NAD+ boosting oral supplement in the United States† (available at www.truniagen.com ), and Niagen™ Plus, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products (www.niagenplus.com ). Pharmaceutical-grade Niagen™ IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. NAD Pharmaceuticals Corp., the Company’s wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases, is conducting research on NB4168, a differentiated small molecule.

Niagen Bioscience’s robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at www.niagenbioscience.com , where copies of press releases, news, and financial information are regularly published.

† Based on revenue per largest U.S. e-commerce marketplace (Jan. 2025 – Dec. 2025)

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Niagen Bioscience, Inc. (“Niagen Bioscience” or the “Company”) intends these statements to be covered by the safe harbor provisions for forward-looking statements in the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements. These include statements about the Company’s strategy, plans, objectives, expectations, and intentions; the development, regulatory status, launch, and commercial success of its products and product candidates; the design, timing, and results of preclinical and clinical studies; the scaling of its Niagen™ Plus platform and telehealth partnerships; its intellectual property position; and its future financial and operating results. Forward-looking statements can often be identified by words such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “should,” “will,” “would,” or the negative of these terms or similar expressions. The absence of these words does not mean a statement is not forward-looking.

Forward-looking statements are based on management’s current expectations, estimates, and assumptions. They are subject to known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied. These risks and uncertainties include, but are not limited to, the following:

Regulatory risks. These include risks related to the regulation of the Company’s products by the U.S. Food and Drug Administration (“FDA”), the Federal Trade Commission (“FTC”), state boards of pharmacy, and comparable foreign authorities. They include the Company’s ability to maintain the regulatory status of nicotinamide riboside (“NR”) as a dietary ingredient, including under its New Dietary Ingredient notifications and Generally Recognized as Safe determinations. They include the Company’s ability to keep NR on the FDA’s list of Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act (Category 1), and the eligibility of NR for compounding under Section 503A. They include changes in FDA policy, guidance, or enforcement priorities for compounded drugs, dietary supplements, or NAD+ precursors. They also include the risk that the FDA, the FTC, or state regulators find the Company’s product claims, labeling, or marketing inadequately substantiated or otherwise noncompliant.

Pharmaceutical development and clinical risks. These include risks related to the NB4168 development program of NAD Pharmaceuticals Corp., the Company’s wholly owned subsidiary. They include the timing, cost, and outcome of planned preclinical, IND-enabling, and clinical activities, and the timing of any Investigational New Drug application or first-in-human study. They include the risk that NB4168 or any other product candidate fails to show adequate bioavailability, exposure, safety, tolerability, efficacy, or pharmacodynamic activity. They include the ability to enroll enough subjects in clinical trials, and the risk that results of preclinical, pilot, open-label, or early-stage studies will not be replicated in larger, controlled trials. They include the risk that clinical or scientific data, including data published as preprints that have not been peer-reviewed, will be interpreted differently by regulators, the scientific community, or the market. They also include the risk that the Company will be unable to obtain marketing approval for any pharmaceutical product, or will obtain approval only for limited indications.

Commercial and competitive risks. These include the growth and profitability of the Company’s product sales and its ability to maintain and grow its sales, marketing, and distribution capabilities. They include the commercial success of Tru Niagen in consumer channels, including e-commerce marketplaces, and of Niagen Plus pharmaceutical-grade intravenous and injectable products. They include the Company’s reliance on third-party clinics, licensed prescribers, telehealth partners, and pharmacies, and its ability to obtain and keep appropriate contracts with FDA-registered 503B outsourcing facilities and state-licensed 503A pharmacies. They include the effect of state laws on telehealth, the corporate practice of medicine, and remote prescribing. They also include competition from other NAD+ precursors, compounded NAD+ products, and dietary supplements, including products that may be mislabeled, adulterated, or marketed with unsubstantiated claims, and changing consumer and clinician perceptions of the Company’s products and of NAD+ science generally.

Intellectual property risks. These include the Company’s ability to maintain, defend, and enforce its existing patents and other intellectual property, and to obtain new patents covering NR, other NAD+ precursors, formulations, and methods of use. They include the expiration of key patents, challenges to the validity or enforceability of the Company’s patents, the risk of infringement claims by third parties, and the cost and uncertainty of intellectual property litigation.

Manufacturing and supply chain risks. These include the Company’s reliance on a single or limited number of third-party suppliers and manufacturers, including suppliers located in China, and its ability to secure adequate quantities of dietary-grade and pharmaceutical-grade Niagen® in a timely manner and to required quality standards. They include risks of product contamination, recalls, or quality failures. They also include the effect of tariffs, trade restrictions, export controls, and geopolitical developments on the Company’s costs and supply.

Financial and general risks. These include the Company’s history of operating losses and its ability to achieve and sustain profitability. They include its future capital requirements, including to fund pharmaceutical development, and the availability of financing on acceptable terms or at all, which could result in dilution to stockholders. They include the Company’s ability to continue to meet Nasdaq listing requirements, product liability and other litigation, inflation and adverse economic or market conditions, and the Company’s ability to attract and retain key personnel.

These and other risks and uncertainties are described in more detail under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission (“SEC”), including its most recent Annual Report on Form 10-K and later Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These filings are available on the SEC’s website at www.sec.gov and in the Investors section of the Company’s website at www.niagenbioscience.com . The risks described above are not exhaustive. New risks emerge from time to time, and the Company cannot predict all risks or assess their impact on its business.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Except as required by applicable law, Niagen Bioscience™ undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changes in assumptions, or otherwise.

Niagen Bioscience Media Contact:
Kendall Knysch, Senior Director of Media Relations & Partnerships
310.405.5227
[email protected]

Niagen Bioscience Investor Relations Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
[email protected]

Source: Niagen Bioscience, Inc

View All News

October 20, 2026

Following a customer-favorite limited release, Niagen NanoCloud™ debuts the Tru Niagen® Skincare category with a first-of-its-kind waterless, precision-dosed sachet technology that keeps Niagen’s benefits protected until activation

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the debut of Tru Niagen® Skincare , a permanent new category in the core Tru Niagen line, led by the Niagen® Skincare Innovation Lab . The inaugural product in this new category is Niagen NanoCloud™ , the first dermatologist-tested topical product powered by Niagen® (patented nicotinamide riboside, or NR, a unique form of vitamin B3), the same ingredient in Tru Niagen® supplements, now in topical form. Delivered in a waterless, precision-dosed sachet that stays sealed until it activates in less than 10 seconds with any water-based serum or moisturizer. NanoCloud is designed to help skin look more youthful, visibly improve skin texture, and help skin look and feel more moisturized1, fitting seamlessly into existing skincare routines without replacing any favorite skincare products. It is available at www.truniagen.com in new packaging.

Following a customer-favorite limited release, Niagen NanoCloud™ debuts the Tru Niagen® Skincare category with a first-of-its-kind waterless, precision-dosed sachet technology that keeps Niagen’s benefits protected until activation

Following a customer-favorite limited release, Niagen NanoCloud™ debuts the Tru Niagen® Skincare category with a first-of-its-kind waterless, precision-dosed sachet technology that keeps Niagen’s benefits protected until activation

Rob Fried, Chief Executive Officer of Niagen Bioscience, said, “Skincare extends Niagen into a large new market, and NanoCloud is the entry point. Customer response to the first limited release gave us the confidence to make NanoCloud a core offering. That is the disciplined approach we intend to take as we build this new category.”

Fortune Business Insights valued the global skincare category at US$122.11 billion in 2025 and projects it to grow to US$227.13 billion by 2034. Within that broader opportunity, the global anti-aging cosmetics market was estimated at US$63.71 billion in 2026 and is projected to reach US$106.98 billion by 2035, according to _Precedence Research _, while Grand View Research projects the U.S. NAD+ products market will grow at a CAGR of 12.2% from 2025 to 2033, with topical products projected to be the fastest-growing segment, underscoring growing demand for science-backed solutions at the intersection of skincare, healthy aging, and longevity.

From Limited Release to Permanent Category

NanoCloud is the debut product from the Niagen Skincare Innovation Lab , the Company’s dedicated program solving a core challenge in NAD+ skincare: water-based NAD+ and precursor products on the market degrade rapidly, long before they ever reach the skin, because the molecules are unstable in water. Niagen Bioscience built NanoCloud with waterless technology to address this challenge. Introduced in March 2026 as a limited release to evaluate customer feedback before a broader launch, NanoCloud was shaped by the community that used it first. Customer demand supported the Company’s decision to launch Niagen NanoCloud as a core Tru Niagen offering and establish Tru Niagen Skincare as a permanent product category. Highlights include:

  • Reviews: NanoCloud holds a 4.8-star average rating. 97% of reviews are four stars or higher.
  • Existing Customers: 49% of purchasers already take Tru Niagen and added NanoCloud to that routine. The top cross-sell product was Tru Niagen Pro 1,000mg.
  • Customer Survey: Based on a post-purchase customer survey, 88% of customers agreed NanoCloud was easy to add to their routine, 85% agreed the format was innovative, and 76% said it felt different from other skincare. Additionally, 78% said they were interested in long-term use.
  • Perception Study: In a 6-week perception study with twice-daily use, 73% of participants agreed their skin appeared smoother after six weeks, and 70% agreed it looked more youthful in as few as four weeks. Nearly 76% said they wanted to keep using NanoCloud. 1

A New Kind of NAD+ Skincare

Water is typically the base ingredient in moisturizers and serums. However, NAD+ and its precursors are unstable in water and in the presence of acidic ingredients such as vitamin C and alpha hydroxy acids (AHAs), and the pH swings common in traditional skincare can accelerate that breakdown. In a water-based formula, NAD+ and precursors like NMN degrade into niacinamide before it reaches the skin.

NanoCloud avoids the problem by keeping Niagen stable. Each sachet is sealed and holds Niagen in a patented nanofiber system made of pullulan and hyaluronic acid. To use one, put a sachet in a dry palm, add a dime-sized amount of water-based serum or moisturizer, and wait 10 seconds. The fibers dissolve completely into a smooth, thin gel with a freshly activated, precision-dosed amount of Niagen every time. For best results, apply twice a day after cleansing. NanoCloud fits seamlessly into existing skincare routines and can be used alongside oral Tru Niagen.

Innovative Ingredient Technology

  • Niagen (patented nicotinamide riboside, or NR): a patented, unique form of vitamin B3 and the foundation of Tru Niagen's NAD+ science. Niagen helps maintain healthy-looking skin. Now available in topical form for the first time.
  • Sodium hyaluronate: a low-molecular-weight hyaluronic acid that delivers moisture.
  • Pullulan: a natural polysaccharide made by fermentation that forms a breathable film to help smooth skin texture.
  • Squalane: a plant-derived emollient similar to the skin's natural lipids that keeps skin soft without a greasy feel.
  • Tocopherol (vitamin E): an antioxidant that helps protect skin from environmental stressors.

Dermatologist-Tested and Clinically Backed

“As a dermatologist, I’m always interested in innovations that translate scientific research into meaningful advances in skincare. I’ve followed the science behind Niagen for years, and it’s exciting to see it applied topically,” said Tiffany Libby, MD, double board-certified dermatologist and Mohs surgeon at Brown Health Medical Group in Rhode Island, and Niagen Bioscience advisor. “What stands out about NanoCloud is its thoughtful formulation and ease of use. Each precisely dosed sachet stays sealed until use and dissolves in seconds with a few drops of my hydrating serum. It’s a simple, seamless addition to my skincare routine.”

Preliminary results from a preprint supported by Niagen Bioscience and published to Preprints.org on March 20, 2026 (not yet peer-reviewed), report that single-use topical Niagen was well tolerated and, on its own, improved skin moisture and smoothness in human clinical testing (doi:10.20944/preprints202603.1657.v1 ).

NanoCloud is dermatologist-tested and free of fragrance, parabens, and phthalates.

Availability

NanoCloud is now available at www.truniagen.com for $59 per 30-sachet unit, with a 2-pack at $99 and a subscription option. Healthcare practitioners, med spas, and aesthetic practices can recommend NanoCloud to their clients on Fullscript and can learn more at pro.truniagen.com .

1Based on a 6-week consumer perception study of 37 female participants aged 35+ who applied the product twice daily. Combined agree/strongly agree responses on a 5-point Likert scale. Individual results may vary.

About Niagen Bioscience

Niagen Bioscience, Inc. (NASDAQ: NAGE) is the global authority in healthy aging and NAD+ (nicotinamide adenine dinucleotide) science. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.

The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.

Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There’s a better way to age.

At the heart of its clinically tested product portfolio is Niagen® (patented nicotinamide riboside, or NR), the most efficient, well-researched, and high-quality NAD+ booster available. Niagen powers the Company’s consumer supplement, Tru Niagen®, the number one NAD+ boosting oral supplement in the United States† (available at www.truniagen.com ), and Niagen™ Plus, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products (www.niagenplus.com ). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. NAD Pharmaceuticals Corp., the Company’s wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases, is conducting research on NB4168, a small differentiated molecule.

Niagen Bioscience’s robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at www.niagenbioscience.com , where copies of press releases, news, and financial information are regularly published.

† Based on revenue per largest U.S. e-commerce marketplace (Jan. 2025 – Dec. 2025)

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements that are not descriptions of historical facts are forward-looking statements. They may often, but not always, be identified by words such as “expects,” “anticipates,” “intends,” “estimates,” “plans,” “potential,” “possible,” “probable,” “believes,” “seeks,” “may,” “will,” “should,” “could,” “predicts,” “projects,” “continue,” “would,” “designed to,” or the negative of such terms or other similar expressions. Forward-looking statements in this release include, but are not limited to, statements regarding the Company’s entry into the skincare market; the establishment of Tru Niagen Skincare as a permanent product category; the expected market acceptance, demand, sales and growth of Niagen NanoCloud and future products from the Niagen Skincare Innovation Lab; the potential for NanoCloud to drive purchases of other Tru Niagen products; the expected benefits, performance and stability of NanoCloud and its sachet and nanofiber technology; and the size and projected growth of the global skincare, anti-aging cosmetics and topical NAD+ markets, and the Company’s ability to address those markets.

Forward-looking statements are based on current expectations and assumptions. They are subject to risks and uncertainties that could cause actual results to differ materially from those described. These risks and uncertainties include, but are not limited to, the Company’s limited experience in the skincare category; whether results from the limited release, consumer perception study and customer survey indicate broader market acceptance or sustained demand; intense competition in the skincare and anti-aging markets, including from companies with greater resources and established brands; the accuracy of third-party market research and projections; whether further research, including peer review of preliminary study results, supports the potential benefits of topical Niagen; our reliance on a single or limited number of third-party suppliers and manufacturers, including for NanoCloud’s sachet and nanofiber components; the Company’s ability to maintain and enforce its existing intellectual property, obtain new patents and avoid infringing the intellectual property of others; changing consumer perceptions of our products; inflationary and adverse economic conditions, and economic and market instability, including as a result of tariffs or trade conflicts; our history of operating losses, and the growth and profitability of our product sales; our ability to maintain and grow sales, marketing and distribution capabilities; mislabeling or other misleading marketing practices by competitors; and the risks and uncertainties associated with our business and financial condition in general, described in our filings with the Securities and Exchange Commission (SEC), including, without limitation, our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q as filed with the SEC.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. All forward-looking statements are qualified in their entirety by this cautionary statement. Niagen Bioscience undertakes no obligation to revise or update this release to reflect events or circumstances after the date of this release.

Niagen Bioscience Media Contact:
Kendall Knysch, Senior Director of Media Relations & Partnerships
310.405.5227
[email protected]

Niagen Bioscience Investor Relations Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
[email protected]

Source: Niagen Bioscience, Inc

View All News

Prompts

Niagen Bioscience, Inc. (ticker NAGE), listed in United States.

Company History

Date Change Detail
Mar 19, 2025 Renamed CHROMADEX CORP. → NIAGEN BIOSCIENCE, INC.
Jun 25, 2008 Renamed CODY RESOURCES, INC. → CHROMADEX CORP.
— Former tickers CDXC

ETFs Holding Niagen Bioscience, Inc.

ETF Weight in ETF Shares Market value As of
LOPP 0.41% 21,000 $ 66.99K Jun 30, 2026
SQLV 0.14% 12,169 $ 38.819K Jun 30, 2026
PSC 0.01% 77,929 $ 248.594K Jun 30, 2026
FEAC 0.01% 715 $ 2,280.85 Jun 30, 2026
DFAS 0.00% 34,822 $ 74.345K Nov 12, 2026
DCOR 0.00% 1,050 $ 2,241.75 Nov 12, 2026
AVSC 0.00% 4,006 $ 8,052.06 Nov 16, 2026